NCT01170650 2021-09-30
PROCEED
Endocyte
Phase 3 Terminated
Clinical Trials
9 trialsNCT01002924 2021-04-08
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Endocyte
Phase 2 Completed
NCT01577654 2021-04-01
TARGET
Endocyte
Phase 2 Completed
NCT00511485 2015-02-27
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Endocyte
Phase 2 Completed
NCT01688791 2015-02-10
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
Endocyte
Phase 1 Terminated
NCT02049281 2015-02-10
A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
Endocyte
Phase 1 Terminated
NCT00507741 2015-01-07
Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)
Endocyte
Phase 2 Completed
NCT00722592 2015-01-07
PRECEDENT
Endocyte
Phase 2 Completed
NCT01953536 2014-12-19
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Endocyte
Phase 2 Withdrawn